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Context. Constipation is a common problem for advanced cancer patients, and
is generally inadequately treated.
Objectives. The aim of this study was to prospectively evaluate the effectiveness
and tolerability of amidotrizoate (AM) in patients unresponsive to current
laxatives.
Methods. A consecutive sample of advanced cancer patients was surveyed.
Inclusion criteria were no bowel movements for three days despite receiving
regular doses of senna or lactulose. AM 50 mL was administered orally; the dose
could be repeated the day after, based on clinical judgment and/or patients’
preference. Age, sex, primary tumor, previous abdominal surgery, chemotherapy
and radiotherapy performed in the previous month, and the use of opioids were
recorded. Nausea, the presence of early satiety, and fluid and food intake also
were measured. Time to first bowel movement was recorded, and adverse effects
attributable to AM.
Results. Ninety-nine patients were surveyed (36 women/63 men). The mean
age was 65.7 years (SD 12.2) and the mean Karnofsky score was 46.8 (SD 9.4).
Patients had no bowel movement for a mean of four days (SD 1.8, range 3e15
days). A total of 80.8% of patients were receiving opioids in doses of mean daily
oral morphine equivalents of 164 mg (SD 235). After AM administration (mean
9.9 6.5 hours), 44.4% of patients had a bowel movement within 24 hours. This
effect was associated with significant improvement of other symptoms and was
independent of age (P¼ 0.513), gender (P¼ 0.090), Karnofsky status (P¼ 0.979),
days of constipation (P¼ 0.198), concomitant chemotherapy (P¼ 0.098) or
radiotherapy (P¼ 0.414), the use of opioids (P¼ 0.361), opioid doses (P¼ 0.420),
and primary tumor (P¼ 0.231). The treatment was more effective in patients who
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422 Vol. 41 No. 2 February 2011Mercadante et al.Conclusion. AM was found to be an easy and inexpensive breakthrough
medication to induce a bowel movement in about 45% of advanced cancer
patients not responsive to common laxatives, with limited and acceptable adverse
effects. J Pain Symptom Manage 2011;41:421e425.  2011 U.S. Cancer Pain Relief
Committee. Published by Elsevier Inc. All rights reserved.Key Words
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Constipation is a common problem for pa-
tients with advanced cancer. It can generate
considerable suffering for patients because of
both unpleasant physical symptoms andpsycho-
logical preoccupations that can arise. In
addition to causing discomfort, constipation
affects daily living, nutritional intake, and so-
cialization, thus compromising quality of life.
Untreated constipation may progress to
obstipation, which may potentially lead to
life-threatening complications associated with
bowel obstruction.1 Although the pathogenesis
is multifactorial, including dietary, mobility,
and disease factors, opioid drugs play a promi-
nent role. Indeed, constipation is considered
the first cause of adverse drug reactions in hos-
pitalized oncology patients.2
The prevalence of constipation among all
patients taking opioids ranges from 50% to
100%.3 Constipation in most patients is gener-
ally inadequately treated. Although a survey in
the UK showed that, for 75% of patients, no
change in the perception of constipation was
observed and severity of constipation was over-
estimated by nurses,4 in an analysis of random-
ized comparative trials, all the laxatives
demonstrated a limited level of efficacy and
a significant number of patients required res-
cue treatments.5
The literature about the use of laxatives by
palliative care units shows that appropriate
doses of laxatives are not commonly adminis-
tered.4Moreover, a combination of drugs acting
with different mechanisms is only minimally
reported.3 This topic remains controversial
because there is no scientific evidence on the
treatment of constipation.
Recently, an expert working group produced
clinical practice recommendations on the man-
agement of constipation in palliative care. Afterinadequate management with traditional laxa-
tives, including a softener and a stimulant, rec-
ommendations suggest second- and third-line
treatments, including rectal suppository or
enema, and manual evacuation, respectively.6
Enemas, besides being stressful, have some po-
tential to cause intestinal perforations. These
maneuvers, particularly manual interventions,
are highly stressful and troublesome for both
patients and personnel.
In recent years, we have been successfully
using amidotrizoate (AM), a hyperosmolar
water-soluble contrast medium, as a second-
line treatment. It is an anionic, bitter-flavored
mixture of sodium diatrizoate, meglumine dia-
trizoate, and a wetting agent, polysorbate 80.7
This substance has been used for diagnostic
purposes and as a first attempt to early resolve
a potentially reversible condition of malignant
bowel obstruction. In combination with other
agents, it has been found to be effective in
the recovery of bowel transit in most patients.8
The aim of this study was to prospectively
evaluate the effectiveness of AM in patients un-
responsive to current laxatives. The secondary
outcome was to assess the tolerability of this
agent.Patients and Methods
All consecutive cancer patients admitted
during a period of one year to an acute pain
relief and palliative care unit were surveyed.
Inclusion criteria were no bowel movements
for three days despite receiving regular doses
of senna or lactulose (four pills/day of senna
or four spoons/day of lactulose, or a combina-
tion of both). Informed consent and ethical
committee approval were obtained. Patients
with a short life expectancy (less than two
weeks), spinal compression, or clear signs of
Table 1
Patient Characteristics
No. of patients 99
Age, mean (SD) 65.7 (12.2)
Karnofsky score, mean (SD) 46.8 (9.4)
Constipation days, mean (SD) 4.0 (1.8)
Opioid doses (in mg oral morphine
equivalents), mean (SD)
164 (235)
Gender (M/F), n 63/36
Previous surgery, n 23
Previous chemotherapy, n 29
Previous radiotherapy, n 3
Primary tumor, n
Lung 30
Genitourinary 19
Gastrointestinal 11
Breast 8
Pancreas 8
Head and neck 6
Other 17
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were hydrated intravenously with a minimum
of 800 mL/day of electrolyte solution; 50 mL
of AM were administered orally, leaving the op-
tion of a repeat dose the day after, based on
clinical judgment and/or patient’s preference
(e.g., to avoid an enema).
Age, sex, primary tumor, previous abdomi-
nal surgery, chemotherapy and radiotherapy
performed in the previous month, and the
use of opioids were recorded. Nausea (using
a scale from 0 to 3, corresponding to ‘‘not at
all,’’ ‘‘slight,’’ ‘‘a lot,’’ and ‘‘severe,’’ respec-
tively), and the presence of early satiety were
also recorded. Reduction of fluid and food in-
take was measured by using a scale from 0 to 3,
corresponding to ‘‘not at all,’’ ‘‘slight,’’ ‘‘a lot,’’
and ‘‘very much,’’ respectively. Time to first
bowel movement was recorded, and adverse ef-
fects attributable to AM. In case of diarrhea,
basal laxatives were discontinued and were
started again after diarrhea resolved.
The primary outcome of this study was to
evaluate the percentage of patients who had
a bowel movement within 24 hours after ad-
ministration of AM. The secondary outcome
was to evaluate the tolerability of this agent.
Statistical Analysis
All continuous data were expressed as
a mean standard deviation (SD) of the
mean. Pearson’s Chi-squared test and Fisher’s
exact test were used to compare the frequency
of AM efficacy vs. gender, primary tumor, previ-
ous abdominal surgery, chemotherapy and ra-
diotherapy performed in the previous month,
early satiety, and adverse effects. One-way analy-
sis of variance and the Mann-Whitney U test
were performed to compare the AM efficacy
with the parametric (age, opioid doses, consti-
pation days) and nonparametric (Karnofsky
score, nausea, fluid reduction, food intake) vari-
ables. The pairedWilcoxon signed-rank test was
used to compare symptom intensity at thediffer-
ent time intervals. The relation between effect
of AMon the bowelmovement and age, Karnof-
sky status, days of constipation, use of opioids,
and opioid doses was performed using a linear
regression model. The hazard ratios (HRs)
and 95% confidence intervals (CIs) were
calculated for gender, primary tumors, previous
abdominal surgery, chemotherapy, or radio-
therapy using a multiple logistic regressionmodel. All P-values were two-sided, and P-values
less than 0.05 were considered statistically sig-
nificant. Data were analyzed by the Epi Info soft-
ware, version 6.0 (Centers for Disease Control
and Prevention, Atlanta, GA) and SPSS Soft-
ware, version 14.0 (SPSS Inc., Chicago, IL).Results
Of the 495 patients admitted in one year,
106 patients presenting with the inclusion cri-
teria were recruited for the study. Seven pa-
tients were excluded because of their short
life expectancy and 99 were finally surveyed.
Patient characteristics are described in Table
1. Patients were constipated for a mean of
four days (SD 1.8, range 3e15 days). A total
of 80.8% (80 of 99 patients) were receiving
opioids in doses of mean daily oral morphine
equivalents of 164 mg (SD 235). Twenty-
three patients had a previous surgery; 29 and
3 patients had received chemotherapy or
radiotherapy in the last month, respectively.
Forty-four patients (44.4%) had a bowel
movement within 24 hours after AM adminis-
tration (mean 9.9 6.5 hours). This effect
was associated with significant improvement
in nausea, hydration, and nutrition observed
(Table 2). Significant improvements also were
observed for early satiety (P< 0.048). Forty-
five patients who did not respond to AM re-
ceived an enema, two of whom responded
within the next 24 hours. After a new dose of
AM (14 patients), seven responded positively.
Table 2
Nausea and Fluid and Food Intake in Patients
Who Had a Bowel Movement Within 24 Hours
After Administration of AM
T0 T1 T2 P
Nausea (0e3) 0.63 (0.9) 0.40 (0.7) 0.28 (0.6) 0.018
Hydration 1.28 (0.8) 0.97 (0.7) 0.88 (0.7) 0.005
Nutrition 1.49 (0.7) 1.09 (0.7) 0.94 (0.7) 0.003
Data are expressed as a mean (SD).
Table 4
Adverse Effects Related to the Study Medication
Diarrhea 19
Vomiting 2
Colic 8
Rumbling 1
Soft feces 2
Abundant feces 3
Fecal incontinence 1
Some patients had more than one adverse effect.
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cording to linear regression analysis) was inde-
pendent of age (P¼ 0.513), Karnofsky status
(P¼ 0.979), days of constipation (P¼ 0.198),
and the use of opioids (P¼ 0.361) and opioid
doses (P¼ 0.420). Moreover, according to
multiple logistic regression analysis, the effect
of AM on bowel movement was independent
of gender (P¼ 0.090), primary tumor (P¼
0.231), concomitant chemotherapy (P¼ 0.098),
or radiotherapy (P¼ 0.414). The treatment
was more effective in patients who had re-
ceived abdominal surgery (HR¼ 3.33; 95%
CI: 1.18, 9.40; P¼ 0.037) (Table 3).
Twenty-nine patients reported adverse ef-
fects related to study medication (Table 4).
As expected, the most frequent adverse effect
(19 patients) was diarrhea. These effects were
limited in time and spontaneously diminished
without specific intervention. Laxatives could
be started again within 48 hours.
Discussion
Patients at admission to an acute palliative
care unit may have many factors contributing
to constipation, including dehydration, meta-
bolic changes, and concurrent medications.
Patients who suffer from severe constipation de-
spite laxative treatment may frequently require
some intervention. In the literature, the use of
breakthrough medications for constipation
resistant to common laxatives has been seldomTable 3
Multiple Logistic Regression Analysis of AM
Efficacy vs. Gender, Primary Tumor, Previous
Abdominal Surgery, Chemotherapy,
or Radiotherapy
Hazard Ratio (95%
Confidence Interval) P
Gender 0.484 (0.21, 1.12) 0.090
Primary tumor 2.571 (0.53, 12.37) 0.231
Abdominal surgery 3.333 (1.18, 9.40) 0.037
Chemotherapy 1.963 (0.79, 4.85) 0.098
Radiotherapy 0.440 (0.03, 5.02) 0.414assessed. Current recommendations by a pan-
European working group suggest second-
and third-line treatments, including rectal
suppository or enema, and manual evacuation,
respectively.6 These maneuvers are universally
considered as a last resort because they are un-
comfortable for patients, particularly manual
interventions.
In this study, AM was effective and well toler-
ated as it induced a bowel movement within
a mean of 10 hours in about 45% of patients
who were regularly receiving laxatives unsuc-
cessfully. This means that about half of patients
who are severely constipated despite the use of
laxatives may avoid invasive and uncomfortable
measures, such as an enema or manual evacua-
tion. AM also was fairly well tolerated in terms
of palatability; it has the flavor of anise. More-
over, symptoms associated with constipation,
such as nausea, early satiety, and fluid and
food intake, significantly improved. Adverse ef-
fects were acceptable and self-limited, with less
than 20% of patients developing diarrhea, ceas-
ing spontaneously within 24 hours.
This effect was obtained regardless of age,
gender, Karnofsky status, days of constipation,
oncological treatments, and the use of opioids
and their doses. Of interest, the treatment
seemed to be more effective in patients with
a previous surgery. It could be supposed that
the use of AM may help patients with postsur-
gical adherence.7 This observation deserves
further investigation.
Studies on the use of laxatives are limited and
often of poor quality, due to the low number of
patients accrued, and differences in laxatives
and doses. In all the studies examined, laxatives
given chronically often required rescue laxa-
tives and no agent was found to be superior to
another one.5 Moreover, no information exists
on the use of rescue laxatives in circumstances
where laxatives given daily to prevent or limit
constipation are ineffective. According to the
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a good alternative to unpleasant procedures.
Recently, peripherally acting mu-antagonists
have been designed to block the peripheral
effects of opioids while sparing central analge-
sia. Methylnaltrexone, given as breakthrough
medication, can reverse opioid-induced consti-
pation by enhancing laxation within four hours
in about 50% of patients. Common adverse
effects experienced included abdominal
cramping and flatulence.9 Costs may be of
concern and future comparative studies should
provide more information about the cost-
effectiveness of these breakthrough treatments.
In conclusion, AM was found to be an easy
and inexpensivemeans to induce a bowelmove-
ment in about 45% of advanced cancer patients
who suffer from severe constipation despite lax-
ative treatment, with limited and acceptable
adverse effects. Data should be considered
with caution, as the study may have some limita-
tions. This was an observational, open-label,
prospective study providing preliminary infor-
mation on the use of a rescue treatment in ad-
vanced cancer patients resistant to laxative
drugs, and no comparison with other treat-
ments was performed. Senna and lactulose
were the laxative medications used before ad-
ministering AM. These are the most common
laxative drugs used in Italy, alone or in combina-
tion, and doses administered were in the range
of the department policy, reflecting common
clinical practice. We also considered an arbi-
trary time of three days to define a constipation
resistant to laxatives. This seems to be a reason-
able timing before starting an alternative inter-
vention. Finally, the study was performed in
a specific setting, that is, an acute palliative
care unit where admitted patients are not neces-
sarily at the end of life andmay still receive anti-
cancer therapies. Further studies with an
appropriate design could provide more data
on the use of rescue medications in patients re-
sistant to laxatives given chronically.Disclosures and Acknowledgments
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